A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk

Published:2013-01-09 Issue:10 Volume:32 Page:1763-1777
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statist. Med.

Author:

Patel Nitin R.¹²,Ankolekar Suresh³,Antonijevic Zoran¹,Rajicic Natasa⁴

Affiliation:

1. Cytel Inc.; 675 Massachusetts Ave. Cambridge MA 02139 U.S.A.

2. Center for Biomedical Innovation; Massachusetts Institute of Technology; Cambridge MA 02139 U.S.A.

3. Maastricht School of Management; Endepolsdomein 150, 6229 EP Maastricht The Netherlands

4. Pfizer Inc.; 235 East 42nd St. New York NY 10017 U.S.A.

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/sim.5731/fullpdf

Reference34 articles.

1. Drug discovery and development in a value-driven health care system;Sarnes;American Health and Drug Benefits,2009

2. Capacity planning under uncertainty for the pharmaceutical industry;Gatica;Chemical Engineering Research and Design,2003

3. A stochastic programming approach for clinical trial planning in new drug development;Colvin;Computers & Chemical Engineering,2008

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Going beyond probability of success: Opportunities for statisticians to influence quantitative decision‐making at the portfolio level;Pharmaceutical Statistics;2024-01-11

2. Drugdevelopr: Planning of Phase Ii/Iii Drug Development Programs with Optimal Sample Size Allocation and Go/No-Go Decision Rules in R;2024

3. Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures;Drug Discovery Today;2023-10

4. Innovations in Clinical Development in Rare Diseases of Children and Adults: Small Populations and/or Small Patients;Pediatric Drugs;2022-10-15

5. A New Comprehensive Approach to Assess the Probability of Success of Development Programs Before Pivotal Trials;Clinical Pharmacology & Therapeutics;2021-12-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3